| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiac Catheterization | 5 | 2020 | 687 | 0.900 |
Why?
|
| Histiocytosis, Sinus | 1 | 2020 | 86 | 0.690 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 9 | 2023 | 2390 | 0.680 |
Why?
|
| Sulfones | 2 | 2011 | 143 | 0.650 |
Why?
|
| Coronary Angiography | 5 | 2014 | 598 | 0.640 |
Why?
|
| Tetralogy of Fallot | 2 | 2023 | 149 | 0.630 |
Why?
|
| Rheumatic Heart Disease | 5 | 2020 | 44 | 0.620 |
Why?
|
| Coronary Artery Disease | 5 | 2017 | 1011 | 0.550 |
Why?
|
| Septal Occluder Device | 1 | 2016 | 49 | 0.530 |
Why?
|
| Ductus Arteriosus | 1 | 2016 | 40 | 0.530 |
Why?
|
| Aortography | 1 | 2016 | 181 | 0.520 |
Why?
|
| India | 11 | 2020 | 301 | 0.490 |
Why?
|
| Eisenmenger Complex | 2 | 2011 | 8 | 0.480 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2016 | 137 | 0.470 |
Why?
|
| Forecasting | 1 | 2017 | 694 | 0.470 |
Why?
|
| Multidetector Computed Tomography | 1 | 2014 | 150 | 0.440 |
Why?
|
| Positron Emission Tomography Computed Tomography | 5 | 2020 | 833 | 0.440 |
Why?
|
| Guideline Adherence | 1 | 2017 | 636 | 0.420 |
Why?
|
| Fluorodeoxyglucose F18 | 5 | 2020 | 1226 | 0.420 |
Why?
|
| Vasodilator Agents | 2 | 2016 | 219 | 0.390 |
Why?
|
| Coronary Vessels | 2 | 2017 | 665 | 0.370 |
Why?
|
| Middle Aged | 53 | 2023 | 86204 | 0.370 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2011 | 133 | 0.370 |
Why?
|
| Diagnostic Imaging | 5 | 2019 | 1162 | 0.370 |
Why?
|
| Pulmonary Artery | 1 | 2014 | 499 | 0.370 |
Why?
|
| Acneiform Eruptions | 2 | 2020 | 7 | 0.370 |
Why?
|
| Piperazines | 2 | 2011 | 2101 | 0.360 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2011 | 125 | 0.360 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2017 | 849 | 0.360 |
Why?
|
| Ventricular Function, Left | 5 | 2017 | 603 | 0.360 |
Why?
|
| Radiopharmaceuticals | 5 | 2017 | 1301 | 0.340 |
Why?
|
| Adult | 39 | 2023 | 77950 | 0.340 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 11 | 2023 | 15862 | 0.340 |
Why?
|
| Female | 60 | 2022 | 141928 | 0.330 |
Why?
|
| Male | 54 | 2021 | 123000 | 0.330 |
Why?
|
| Mitral Valve Stenosis | 3 | 2020 | 50 | 0.330 |
Why?
|
| Sarcopenia | 3 | 2021 | 110 | 0.320 |
Why?
|
| Balloon Valvuloplasty | 2 | 2020 | 31 | 0.320 |
Why?
|
| Pyrazoles | 4 | 2019 | 1471 | 0.300 |
Why?
|
| Humans | 80 | 2023 | 261506 | 0.300 |
Why?
|
| Aged | 36 | 2023 | 70117 | 0.290 |
Why?
|
| Risk Assessment | 2 | 2017 | 6869 | 0.290 |
Why?
|
| Young Adult | 18 | 2023 | 21445 | 0.290 |
Why?
|
| Echocardiography | 6 | 2023 | 1182 | 0.290 |
Why?
|
| Adolescent | 20 | 2023 | 31252 | 0.290 |
Why?
|
| Administration, Oral | 8 | 2020 | 1544 | 0.290 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2023 | 1664 | 0.290 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2006 | 66 | 0.290 |
Why?
|
| Cardiovascular Diseases | 2 | 2017 | 2195 | 0.280 |
Why?
|
| Mitral Valve | 2 | 2020 | 271 | 0.270 |
Why?
|
| Follow-Up Studies | 15 | 2021 | 14889 | 0.270 |
Why?
|
| Aged, 80 and over | 18 | 2023 | 29902 | 0.270 |
Why?
|
| Retrospective Studies | 29 | 2023 | 37905 | 0.270 |
Why?
|
| Heart Rate | 2 | 2020 | 737 | 0.270 |
Why?
|
| Pancreatic Neoplasms | 5 | 2023 | 5061 | 0.260 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 2017 | 244 | 0.250 |
Why?
|
| Hodgkin Disease | 3 | 2017 | 1429 | 0.240 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2016 | 343 | 0.240 |
Why?
|
| Adenine | 7 | 2023 | 631 | 0.240 |
Why?
|
| Pyrimidines | 4 | 2019 | 3518 | 0.230 |
Why?
|
| Endocarditis, Bacterial | 1 | 2005 | 128 | 0.230 |
Why?
|
| Dextrocardia | 1 | 2003 | 10 | 0.230 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2022 | 1105 | 0.220 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2003 | 126 | 0.220 |
Why?
|
| Thrombocytopenia | 2 | 2018 | 846 | 0.210 |
Why?
|
| Child | 14 | 2023 | 29154 | 0.210 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2019 | 7551 | 0.210 |
Why?
|
| Intra-Abdominal Fat | 2 | 2019 | 95 | 0.210 |
Why?
|
| Heart Ventricles | 2 | 2017 | 846 | 0.200 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2018 | 1724 | 0.200 |
Why?
|
| Hypertension, Pulmonary | 1 | 2006 | 462 | 0.200 |
Why?
|
| Odds Ratio | 6 | 2017 | 2316 | 0.200 |
Why?
|
| Treatment Outcome | 19 | 2020 | 32848 | 0.190 |
Why?
|
| Prospective Studies | 9 | 2022 | 12873 | 0.190 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2021 | 173 | 0.190 |
Why?
|
| Tertiary Care Centers | 2 | 2020 | 403 | 0.190 |
Why?
|
| Flecainide | 1 | 2020 | 27 | 0.190 |
Why?
|
| Cranial Nerve Diseases | 1 | 2021 | 73 | 0.190 |
Why?
|
| Quality of Life | 4 | 2023 | 4532 | 0.190 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2021 | 247 | 0.180 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 3 | 2023 | 923 | 0.180 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2021 | 123 | 0.180 |
Why?
|
| Diagnosis, Differential | 9 | 2019 | 4744 | 0.180 |
Why?
|
| Body Composition | 3 | 2017 | 595 | 0.180 |
Why?
|
| Sildenafil Citrate | 2 | 2011 | 53 | 0.170 |
Why?
|
| Logistic Models | 5 | 2017 | 3441 | 0.170 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2020 | 99 | 0.170 |
Why?
|
| Risk Factors | 13 | 2022 | 17523 | 0.170 |
Why?
|
| Retinoids | 1 | 2019 | 164 | 0.170 |
Why?
|
| CTLA-4 Antigen | 2 | 2020 | 657 | 0.170 |
Why?
|
| Antibodies, Bispecific | 1 | 2022 | 246 | 0.170 |
Why?
|
| Absorptiometry, Photon | 1 | 2019 | 239 | 0.170 |
Why?
|
| Leukemia | 2 | 2018 | 1635 | 0.170 |
Why?
|
| Sternum | 1 | 2019 | 100 | 0.160 |
Why?
|
| Piperidines | 6 | 2021 | 1035 | 0.160 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2019 | 4757 | 0.160 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2017 | 323 | 0.160 |
Why?
|
| Plasmacytoma | 1 | 2019 | 111 | 0.160 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2020 | 172 | 0.160 |
Why?
|
| Multiple Myeloma | 2 | 2020 | 2138 | 0.160 |
Why?
|
| Predictive Value of Tests | 3 | 2016 | 4892 | 0.160 |
Why?
|
| Neoplasms | 7 | 2021 | 15193 | 0.150 |
Why?
|
| Purines | 2 | 2011 | 273 | 0.150 |
Why?
|
| Platelet Factor 4 | 1 | 2017 | 35 | 0.150 |
Why?
|
| Bursitis | 1 | 2017 | 10 | 0.150 |
Why?
|
| Quinolines | 1 | 2020 | 383 | 0.150 |
Why?
|
| Breast Density | 1 | 2017 | 18 | 0.150 |
Why?
|
| Survival Rate | 7 | 2021 | 12221 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2021 | 3251 | 0.150 |
Why?
|
| Benzazepines | 1 | 2017 | 108 | 0.150 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 1 | 2016 | 17 | 0.140 |
Why?
|
| Phenylurea Compounds | 1 | 2020 | 580 | 0.140 |
Why?
|
| Trimetazidine | 1 | 2016 | 1 | 0.140 |
Why?
|
| Hypercalcemia | 1 | 2017 | 137 | 0.140 |
Why?
|
| Metoprolol | 1 | 2016 | 28 | 0.140 |
Why?
|
| Polytetrafluoroethylene | 1 | 2017 | 113 | 0.140 |
Why?
|
| Drug Eruptions | 1 | 2018 | 256 | 0.140 |
Why?
|
| Anticoagulants | 2 | 2018 | 787 | 0.140 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2019 | 301 | 0.140 |
Why?
|
| Neoplasm Staging | 8 | 2019 | 13658 | 0.140 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2018 | 181 | 0.140 |
Why?
|
| Shoulder Joint | 1 | 2017 | 82 | 0.140 |
Why?
|
| Severity of Illness Index | 6 | 2016 | 4320 | 0.140 |
Why?
|
| Spinal Cord Diseases | 1 | 2017 | 90 | 0.140 |
Why?
|
| Postoperative Complications | 3 | 2017 | 5542 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2019 | 10035 | 0.140 |
Why?
|
| Aortic Valve | 1 | 2020 | 581 | 0.140 |
Why?
|
| Cancer Survivors | 2 | 2021 | 650 | 0.140 |
Why?
|
| Atrial Fibrillation | 2 | 2020 | 719 | 0.130 |
Why?
|
| Diaphragm | 1 | 2017 | 181 | 0.130 |
Why?
|
| Stroke Volume | 5 | 2017 | 577 | 0.130 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2020 | 314 | 0.130 |
Why?
|
| Acellular Dermis | 1 | 2017 | 103 | 0.130 |
Why?
|
| Angioplasty, Balloon, Coronary | 2 | 2017 | 314 | 0.130 |
Why?
|
| Morbidity | 1 | 2017 | 397 | 0.130 |
Why?
|
| Indazoles | 1 | 2017 | 297 | 0.130 |
Why?
|
| Child, Preschool | 5 | 2017 | 16273 | 0.130 |
Why?
|
| Sympathetic Nervous System | 1 | 2016 | 159 | 0.130 |
Why?
|
| Heparin | 1 | 2017 | 360 | 0.130 |
Why?
|
| Postoperative Care | 1 | 2019 | 739 | 0.130 |
Why?
|
| Mediastinal Neoplasms | 1 | 2019 | 423 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2017 | 4938 | 0.130 |
Why?
|
| Aortic Valve Stenosis | 1 | 2020 | 476 | 0.130 |
Why?
|
| Carcinoma, Small Cell | 1 | 2017 | 408 | 0.130 |
Why?
|
| Calcinosis | 1 | 2018 | 423 | 0.120 |
Why?
|
| Salvage Therapy | 2 | 2020 | 2054 | 0.120 |
Why?
|
| Cell Death | 1 | 2017 | 671 | 0.120 |
Why?
|
| Digestive System Diseases | 1 | 2014 | 35 | 0.120 |
Why?
|
| Electrocardiography | 1 | 2020 | 1145 | 0.120 |
Why?
|
| Collateral Circulation | 1 | 2014 | 59 | 0.120 |
Why?
|
| Receptors, Adrenergic, beta-3 | 1 | 2014 | 16 | 0.120 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2016 | 180 | 0.120 |
Why?
|
| Tumor Burden | 2 | 2018 | 1987 | 0.120 |
Why?
|
| Gonadal Disorders | 1 | 2013 | 8 | 0.120 |
Why?
|
| Urologic Diseases | 1 | 2014 | 78 | 0.120 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2019 | 600 | 0.120 |
Why?
|
| Stomach Neoplasms | 2 | 2019 | 2278 | 0.120 |
Why?
|
| Antibodies | 1 | 2017 | 838 | 0.120 |
Why?
|
| Myxoma | 1 | 2014 | 63 | 0.120 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 469 | 0.120 |
Why?
|
| Myocardial Revascularization | 1 | 2014 | 134 | 0.120 |
Why?
|
| Sulfonamides | 2 | 2021 | 1823 | 0.120 |
Why?
|
| Pulmonary Circulation | 1 | 2014 | 131 | 0.120 |
Why?
|
| Electronic Health Records | 2 | 2018 | 929 | 0.120 |
Why?
|
| Comorbidity | 1 | 2020 | 2352 | 0.120 |
Why?
|
| Ultrasonography, Mammary | 1 | 2016 | 380 | 0.120 |
Why?
|
| Image-Guided Biopsy | 1 | 2016 | 327 | 0.120 |
Why?
|
| Methotrexate | 1 | 2017 | 999 | 0.120 |
Why?
|
| Hemodynamics | 2 | 2011 | 935 | 0.110 |
Why?
|
| Coronary Circulation | 1 | 2014 | 253 | 0.110 |
Why?
|
| Urogenital Neoplasms | 1 | 2014 | 108 | 0.110 |
Why?
|
| Thrombosis | 2 | 2015 | 781 | 0.110 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 1 | 2013 | 57 | 0.110 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 450 | 0.110 |
Why?
|
| Contrast Media | 3 | 2015 | 1472 | 0.110 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2017 | 436 | 0.110 |
Why?
|
| Venous Thromboembolism | 1 | 2018 | 335 | 0.110 |
Why?
|
| Radial Artery | 1 | 2013 | 50 | 0.110 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2013 | 80 | 0.110 |
Why?
|
| INDEL Mutation | 1 | 2013 | 112 | 0.110 |
Why?
|
| Urogenital System | 1 | 2013 | 59 | 0.110 |
Why?
|
| Prosthesis Design | 1 | 2016 | 749 | 0.110 |
Why?
|
| Carcinoma, Lobular | 1 | 2017 | 611 | 0.110 |
Why?
|
| Digestive System | 1 | 2013 | 114 | 0.110 |
Why?
|
| Liver Diseases | 1 | 2018 | 574 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2016 | 5539 | 0.110 |
Why?
|
| Ventricular Remodeling | 1 | 2014 | 248 | 0.110 |
Why?
|
| Hypnotics and Sedatives | 1 | 2014 | 218 | 0.110 |
Why?
|
| Breast Diseases | 1 | 2014 | 201 | 0.110 |
Why?
|
| Femoral Artery | 1 | 2013 | 210 | 0.100 |
Why?
|
| Radiation Injuries | 1 | 2020 | 1411 | 0.100 |
Why?
|
| Neoadjuvant Therapy | 4 | 2023 | 4975 | 0.100 |
Why?
|
| Time-to-Treatment | 1 | 2014 | 292 | 0.100 |
Why?
|
| Blood Vessels | 1 | 2013 | 217 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 864 | 0.100 |
Why?
|
| Reproducibility of Results | 3 | 2023 | 6009 | 0.100 |
Why?
|
| Imidazoles | 1 | 2017 | 999 | 0.100 |
Why?
|
| Lymph Nodes | 2 | 2020 | 2967 | 0.100 |
Why?
|
| Osteosarcoma | 1 | 2019 | 929 | 0.100 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 1084 | 0.100 |
Why?
|
| Radiographic Image Enhancement | 1 | 2014 | 402 | 0.100 |
Why?
|
| Exercise Test | 2 | 2016 | 312 | 0.100 |
Why?
|
| Cardiology | 1 | 2017 | 530 | 0.100 |
Why?
|
| Time Factors | 7 | 2020 | 12926 | 0.100 |
Why?
|
| Erectile Dysfunction | 1 | 2013 | 212 | 0.090 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2013 | 297 | 0.090 |
Why?
|
| Lymphatic Metastasis | 2 | 2019 | 4844 | 0.090 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2017 | 1299 | 0.090 |
Why?
|
| Societies, Medical | 1 | 2017 | 1335 | 0.090 |
Why?
|
| Pancreatectomy | 1 | 2014 | 652 | 0.090 |
Why?
|
| Carcinoma | 1 | 2022 | 2578 | 0.090 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 4298 | 0.090 |
Why?
|
| Energy Metabolism | 1 | 2016 | 992 | 0.090 |
Why?
|
| Neoplasm, Residual | 3 | 2023 | 1656 | 0.090 |
Why?
|
| Venous Thrombosis | 1 | 2013 | 384 | 0.090 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2017 | 1216 | 0.090 |
Why?
|
| Endothelium, Vascular | 1 | 2014 | 891 | 0.090 |
Why?
|
| Ultrasonography | 1 | 2016 | 1863 | 0.090 |
Why?
|
| Graft Rejection | 1 | 2014 | 834 | 0.090 |
Why?
|
| Heart | 1 | 2016 | 1223 | 0.090 |
Why?
|
| Radiotherapy | 2 | 2017 | 1824 | 0.090 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 4314 | 0.090 |
Why?
|
| Stem Cell Transplantation | 1 | 2016 | 1360 | 0.090 |
Why?
|
| Prognosis | 8 | 2021 | 21713 | 0.080 |
Why?
|
| Coronary Disease | 1 | 2013 | 764 | 0.080 |
Why?
|
| Biomarkers | 3 | 2016 | 5047 | 0.080 |
Why?
|
| Breast Neoplasms | 3 | 2019 | 15694 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 3552 | 0.080 |
Why?
|
| Takayasu Arteritis | 1 | 2008 | 21 | 0.080 |
Why?
|
| Antineoplastic Agents | 3 | 2018 | 14289 | 0.080 |
Why?
|
| Sensitivity and Specificity | 5 | 2017 | 4971 | 0.080 |
Why?
|
| E-Selectin | 1 | 2008 | 103 | 0.080 |
Why?
|
| Neoplasms, Second Primary | 1 | 2017 | 1350 | 0.080 |
Why?
|
| Kidney Transplantation | 1 | 2014 | 755 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 2 | 2018 | 4367 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2020 | 7702 | 0.080 |
Why?
|
| Recurrence | 4 | 2018 | 4758 | 0.080 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2008 | 121 | 0.080 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 7789 | 0.080 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2008 | 221 | 0.080 |
Why?
|
| Gene Expression | 1 | 2016 | 3570 | 0.080 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 1450 | 0.080 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2018 | 2104 | 0.070 |
Why?
|
| Mutation | 3 | 2022 | 15179 | 0.070 |
Why?
|
| Genomics | 1 | 2018 | 2738 | 0.070 |
Why?
|
| Hemoptysis | 1 | 2006 | 36 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2019 | 6207 | 0.070 |
Why?
|
| Anthropometry | 2 | 2017 | 269 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2014 | 1756 | 0.070 |
Why?
|
| Lymphoma | 1 | 2015 | 1467 | 0.070 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 2576 | 0.070 |
Why?
|
| Vinblastine | 2 | 2017 | 453 | 0.070 |
Why?
|
| Inflammation | 1 | 2016 | 2522 | 0.070 |
Why?
|
| Bleomycin | 2 | 2017 | 467 | 0.070 |
Why?
|
| Combined Modality Therapy | 4 | 2019 | 8865 | 0.070 |
Why?
|
| Chest Pain | 1 | 2006 | 155 | 0.070 |
Why?
|
| Radiotherapy Dosage | 3 | 2019 | 3842 | 0.070 |
Why?
|
| Incidence | 3 | 2021 | 5673 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2016 | 4549 | 0.070 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2014 | 787 | 0.070 |
Why?
|
| Infant | 2 | 2016 | 13310 | 0.070 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 2173 | 0.060 |
Why?
|
| Models, Biological | 1 | 2014 | 3254 | 0.060 |
Why?
|
| Myocardial Infarction | 1 | 2014 | 1374 | 0.060 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2017 | 2326 | 0.060 |
Why?
|
| Dacarbazine | 2 | 2017 | 485 | 0.060 |
Why?
|
| Exercise | 2 | 2023 | 1183 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2017 | 7226 | 0.060 |
Why?
|
| Patient Selection | 3 | 2017 | 2055 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 3022 | 0.060 |
Why?
|
| Acenocoumarol | 1 | 2002 | 1 | 0.060 |
Why?
|
| Oxygen | 1 | 2006 | 754 | 0.050 |
Why?
|
| Catheters | 1 | 2023 | 126 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2020 | 2803 | 0.050 |
Why?
|
| Muscle, Skeletal | 2 | 2021 | 1270 | 0.050 |
Why?
|
| Recovery of Function | 2 | 2016 | 703 | 0.050 |
Why?
|
| Gene Frequency | 2 | 2016 | 1163 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2015 | 1323 | 0.050 |
Why?
|
| Angiography | 1 | 2023 | 360 | 0.050 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 4638 | 0.050 |
Why?
|
| Prevalence | 3 | 2013 | 3260 | 0.050 |
Why?
|
| Computed Tomography Angiography | 1 | 2023 | 234 | 0.050 |
Why?
|
| Voltage-Gated Sodium Channel Blockers | 1 | 2020 | 4 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2017 | 6100 | 0.050 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2002 | 303 | 0.050 |
Why?
|
| Disease Progression | 3 | 2017 | 6682 | 0.050 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2021 | 164 | 0.050 |
Why?
|
| Exercise Therapy | 1 | 2023 | 288 | 0.050 |
Why?
|
| Catheterization | 1 | 2002 | 410 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2017 | 3472 | 0.040 |
Why?
|
| Doxorubicin | 2 | 2017 | 3005 | 0.040 |
Why?
|
| Salivary Glands | 1 | 2019 | 130 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2019 | 3890 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 11538 | 0.040 |
Why?
|
| Biopsy | 2 | 2018 | 3443 | 0.040 |
Why?
|
| Professional Practice Gaps | 1 | 2017 | 15 | 0.040 |
Why?
|
| Cyclic Nucleotide-Gated Cation Channels | 1 | 2017 | 17 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2019 | 486 | 0.040 |
Why?
|
| Molecular Probe Techniques | 1 | 2017 | 46 | 0.040 |
Why?
|
| Pattern Recognition, Automated | 1 | 2018 | 125 | 0.040 |
Why?
|
| Ifosfamide | 1 | 2018 | 344 | 0.040 |
Why?
|
| Subacute Combined Degeneration | 1 | 2017 | 16 | 0.040 |
Why?
|
| Angioplasty | 1 | 2017 | 94 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2019 | 371 | 0.040 |
Why?
|
| Deuterium Oxide | 1 | 2017 | 20 | 0.040 |
Why?
|
| Ticlopidine | 1 | 2017 | 95 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2023 | 1294 | 0.040 |
Why?
|
| Retreatment | 1 | 2018 | 452 | 0.040 |
Why?
|
| Subcutaneous Fat | 1 | 2017 | 92 | 0.040 |
Why?
|
| Injections, Spinal | 1 | 2017 | 257 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2023 | 1048 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2018 | 587 | 0.040 |
Why?
|
| Homocysteine | 1 | 2017 | 138 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 799 | 0.030 |
Why?
|
| Cardiovascular Agents | 1 | 2017 | 128 | 0.030 |
Why?
|
| Vidarabine | 1 | 2021 | 1341 | 0.030 |
Why?
|
| Survivors | 1 | 2022 | 1031 | 0.030 |
Why?
|
| Etoposide | 1 | 2018 | 870 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2002 | 732 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2017 | 257 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2021 | 2232 | 0.030 |
Why?
|
| Microsatellite Instability | 1 | 2018 | 400 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2019 | 669 | 0.030 |
Why?
|
| Fatigue | 1 | 2022 | 1239 | 0.030 |
Why?
|
| Ipilimumab | 1 | 2020 | 710 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2017 | 289 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2016 | 756 | 0.030 |
Why?
|
| Carboplatin | 1 | 2018 | 823 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2021 | 899 | 0.030 |
Why?
|
| Tissue Survival | 1 | 2014 | 15 | 0.030 |
Why?
|
| Neutropenia | 1 | 2019 | 968 | 0.030 |
Why?
|
| Brachial Artery | 1 | 2014 | 38 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2020 | 840 | 0.030 |
Why?
|
| Echocardiography, Doppler | 1 | 2015 | 180 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2017 | 462 | 0.030 |
Why?
|
| Incidental Findings | 1 | 2016 | 272 | 0.030 |
Why?
|
| Folic Acid | 1 | 2017 | 349 | 0.030 |
Why?
|
| Amplified Fragment Length Polymorphism Analysis | 1 | 2014 | 2 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2016 | 374 | 0.030 |
Why?
|
| Receptors, Adrenergic, beta-1 | 1 | 2014 | 16 | 0.030 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2014 | 121 | 0.030 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2014 | 71 | 0.030 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2014 | 23 | 0.030 |
Why?
|
| Aspirin | 1 | 2017 | 455 | 0.030 |
Why?
|
| ROC Curve | 1 | 2017 | 1183 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 1489 | 0.030 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2013 | 29 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2018 | 785 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2021 | 3001 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2014 | 192 | 0.030 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2014 | 239 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 1742 | 0.030 |
Why?
|
| Glycolysis | 1 | 2016 | 519 | 0.030 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2017 | 690 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2017 | 550 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 2014 | 183 | 0.030 |
Why?
|
| Radiotherapy, Conformal | 1 | 2019 | 902 | 0.030 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2014 | 305 | 0.030 |
Why?
|
| Hemostatic Techniques | 1 | 2013 | 38 | 0.030 |
Why?
|
| Punctures | 1 | 2013 | 104 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2014 | 445 | 0.030 |
Why?
|
| Remission Induction | 1 | 2019 | 3569 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 10001 | 0.030 |
Why?
|
| Acute Disease | 1 | 2018 | 2422 | 0.030 |
Why?
|
| Troponin I | 1 | 2013 | 127 | 0.030 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2017 | 342 | 0.030 |
Why?
|
| Coronary Artery Bypass | 1 | 2017 | 708 | 0.030 |
Why?
|
| Pleural Neoplasms | 1 | 2017 | 470 | 0.030 |
Why?
|
| Reoperation | 1 | 2017 | 1382 | 0.030 |
Why?
|
| Nephrectomy | 1 | 2017 | 779 | 0.030 |
Why?
|
| Cardiotonic Agents | 1 | 2013 | 151 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 2283 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1945 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 1972 | 0.030 |
Why?
|
| Breast | 1 | 2019 | 1344 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2014 | 665 | 0.030 |
Why?
|
| Mesothelioma | 1 | 2017 | 544 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 2315 | 0.030 |
Why?
|
| Age Distribution | 1 | 2013 | 698 | 0.030 |
Why?
|
| Mesoderm | 1 | 2013 | 404 | 0.020 |
Why?
|
| Heart Valve Diseases | 1 | 2013 | 193 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2018 | 1648 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2019 | 1959 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2014 | 1290 | 0.020 |
Why?
|
| Radiography, Interventional | 1 | 2013 | 305 | 0.020 |
Why?
|
| Abdomen | 1 | 2013 | 332 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2019 | 2295 | 0.020 |
Why?
|
| Pelvis | 1 | 2013 | 362 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2018 | 9180 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2014 | 602 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2016 | 1819 | 0.020 |
Why?
|
| Sex Factors | 1 | 2016 | 2139 | 0.020 |
Why?
|
| Graft Survival | 1 | 2014 | 1062 | 0.020 |
Why?
|
| Kinetics | 1 | 2013 | 2049 | 0.020 |
Why?
|
| Stomach | 1 | 2013 | 387 | 0.020 |
Why?
|
| Lung | 1 | 2021 | 3151 | 0.020 |
Why?
|
| Biomarkers, Tumor | 2 | 2021 | 10331 | 0.020 |
Why?
|
| Ultrasonography, Interventional | 1 | 2013 | 429 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2013 | 577 | 0.020 |
Why?
|
| Texas | 1 | 2021 | 6311 | 0.020 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 1249 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2003 | 8223 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2017 | 2203 | 0.020 |
Why?
|
| Body Weight | 1 | 2014 | 1293 | 0.020 |
Why?
|
| Alleles | 1 | 2016 | 2437 | 0.020 |
Why?
|
| Mass Screening | 1 | 2018 | 1509 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2014 | 1014 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2014 | 607 | 0.020 |
Why?
|
| Rituximab | 1 | 2014 | 1528 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2014 | 1353 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 925 | 0.020 |
Why?
|
| Azathioprine | 1 | 2008 | 66 | 0.020 |
Why?
|
| Proton Therapy | 1 | 2019 | 1577 | 0.020 |
Why?
|
| Decision Making | 1 | 2016 | 1287 | 0.020 |
Why?
|
| Obesity | 1 | 2021 | 2884 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 5112 | 0.020 |
Why?
|
| Mammography | 1 | 2014 | 1010 | 0.020 |
Why?
|
| Genotype | 1 | 2016 | 4109 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2016 | 2086 | 0.020 |
Why?
|
| Palliative Care | 1 | 2019 | 2037 | 0.020 |
Why?
|
| Cisplatin | 1 | 2014 | 2432 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 7548 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2020 | 9244 | 0.020 |
Why?
|
| Pregnancy | 1 | 2020 | 7573 | 0.020 |
Why?
|
| Algorithms | 1 | 2018 | 3890 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2014 | 945 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 3981 | 0.020 |
Why?
|
| Cytokines | 1 | 2016 | 2809 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2014 | 1946 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 14551 | 0.010 |
Why?
|
| Phenotype | 1 | 2014 | 6295 | 0.010 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2002 | 100 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 1375 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 5687 | 0.010 |
Why?
|
| Probability | 1 | 2002 | 866 | 0.010 |
Why?
|
| Heart Atria | 1 | 2002 | 352 | 0.010 |
Why?
|